Bluefin Biomedicine Patents – Insights & Stats (Updated 2023)

Bluefin Biomedicine has a total of 44 patents globally, out of which 9 have been granted. Of these 44 patents, more than 81% patents are active. The United States of America is where Bluefin Biomedicine has filed the maximum number of patents, followed by Canada and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Bluefin Biomedicine.

Bluefin Biomedicine was founded in 2016. Bluefin Biomedicine is a privately held firm that focuses on the discovery of novel cancer antigens and the development of next-generation cancer treatments. The complex tumor specimens are analysed using patented, state-of-the-art protein detection techniques to identify cancer antigens that are expressed differently and can be targeted by antibody treatments.

Do read about some of the most popular patents of Bluefin Biomedicine which have been covered by us in this article and also you can find Bluefin Biomedicine patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Bluefin Biomedicine patent portfolio.

How many patents does Bluefin Biomedicine have?

Bluefin Biomedicine has a total of 44 patents globally. These patents belong to 10 unique patent families. Out of 44 patents, 36 patents are active.

How Many Patents did Bluefin Biomedicine File Every Year?

Bluefin Biomedicine Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantBluefin Biomedicine Applications FiledBluefin Biomedicine Patents Granted
202324
202254
20211
20202
201911
201820
201712
20142

How many Bluefin Biomedicine patents are Alive/Dead?

Worldwide Patents

Bluefin Biomedicine Patent Portfolio

How Many Patents did Bluefin Biomedicine File in Different Countries?

Bluefin Biomedicine Worldwide Patent Filing

Countries in which Bluefin Biomedicine Filed Patents

CountryPatent
United States of America13
Canada7
Japan6
Europe6
China3
Hong Kong (S.A.R.)2

Where are Research Centers of Bluefin Biomedicine Patents Located?

The Research Center for Bluefin Biomedicine is the United States of America.

What Percentage of Bluefin Biomedicine US Patent Applications Were Granted?

Bluefin Biomedicine (Excluding its subsidiaries) has filed 10 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 5 have been granted leading to a grant rate of 100%.

Below are the key stats of Bluefin Biomedicine patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Bluefin Biomedicine?

Law FirmTotal ApplicationsSuccess Rate
Mccarter & English Llp Boston6100.00%
Morgan Lewis & Bockius Llp Ph20%
Klarquist Sparkman Llp1100.00%
Procopio Cory Hargreaves & Savitch Llp1100.00%

List of Bluefin Biomedicine patents

Bluefin Biomedicine PatentsTitle
US11702481B2Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
US11634486B2Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
US11434303B2Anti-Ly6H Antibodies And Antibody Drug Conjugates
US11312769B2Anti-Tmeff1 Antibodies And Antibody Drug Conjugates
US11267886B2Anti-Ilt3 Antibodies And Antibody Drug Conjugates
US11248054B2Anti-Il1Rap Antibodies And Antibody Drug Conjugates
US10208125B2Anti-Mucin 1 Binding Agents And Uses Thereof
US20230331839A1Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
US20230192885A1Anti-Ly6H Antibodies And Antibody Drug Conjugates
US20230069760A1Anti-Vtcn1 Antibodies And Antibody Drug Conjugates
US20220298239A1Anti-Tmeff1 Antibodies And Antibody Drug Conjugates
US20220267455A1Anti-Il1Rap Antibodies And Antibody Drug Conjugates
US20220227863A1Anti-Ilt3 Antibodies And Antibody Drug Conjugates
EP3580239A4Anti-Ilt3 Antibodies And Antibody Drug Conjugates
EP3638697A4Anti-Il1Rap Antibodies And Antibody Drug Conjugates
EP3601360A4Anti-Tmeff1 Antibodies And Antibody Drug Conjugates
EP3612567A4Anti-Vtcn1 Antibodies And Antibody Drug Conjugates
EP3559043A4Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
EP3554544A4Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
CN110997725AAnti-Il1Rap Antibodies And Antibody Drug Conjugates
CN110234348AAnti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
CN110121507AAnti-Sez6L2 Antibodies And Antibody Drug Conjugates
CA3066918A1Anti-Il1Rap Antibodies And Antibody Drug Conjugates
CA3064697A1Anti-Vtcn1 Antibodies And Antibody Drug Conjugates
CA3055305A1Anti-Tmeff1 Antibodies And Antibody Drug Conjugates
CA3053164A1Anti-Ilt3 Antibodies And Antibody Drug Conjugates
CA3048224A1Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
CA3047115A1Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
CA2954859A1Anti-Mucin 1 Binding Agents And Uses Thereof
JP7350313B2Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
JP7264482B2Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
JP2023022328A5Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
JP2023093685AAnti-Il1Rap Antibodies And Antibody Drug Conjugates
JP2022101693A5Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
HK40027179AAnti-Il1Rap Antibodies And Antibody Drug Conjugates
HK40014209AAnti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
WO2018175740A8Anti-Tmeff1 Antibodies And Antibody Drug Conjugates
WO2018231827A9Anti-Il1Rap Antibodies And Antibody Drug Conjugates
WO2018119351A8Anti-Sez6L2 Antibodies And Antibody Drug Conjugates
WO2019006162A1Anti-Ly6H Antibodies And Antibody Drug Conjugates
WO2018195302A1Anti-Vtcn1 Antibodies And Antibody Drug Conjugates
WO2018148494A1Anti-Ilt3 Antibodies And Antibody Drug Conjugates
WO2018112334A1Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof
JP2020527332A5Anti-Il1Rap Antibodies And Antibody Drug Conjugates

What are Bluefin Biomedicine key innovation segments?

What Technologies are Covered by Bluefin Biomedicine?

The chart below distributes patents filed by Bluefin Biomedicine in different countries on the basis of the technology protected in patents. It also represents the markets where Bluefin Biomedicine thinks it’s important to protect particular technology inventions.

R&D Focus: How has Bluefin Biomedicine search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Bluefin Biomedicine?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.